INREBIC 100 mg, hard capsule 120 capsules
Active ingredients: DICHLORHYDRATE DE FÉDRATINIB MONOHYDRATÉ, FÉDRATINIB
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule120 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- INREBIC 100 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 120 gélule(s)
- Marketing authorisation holder
- BRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- Reimbursement according to BDPM
- 30%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 21 Sept 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65716809CIP73023262CIP133400930232620Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FÉDRATINIBgélule | 100 mg · une gélule | FT |
| DICHLORHYDRATE DE FÉDRATINIB MONOHYDRATÉgélule | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.